Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes - PubMed (original) (raw)
Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes
Gareth Watkins et al. Prostaglandins Leukot Essent Fatty Acids. 2005 Apr.
Abstract
SPARC (secreted protein acidic and rich in cystein), also known as osteonectin and BM40, is a 32 kDa secreted glycoprotein that interacts with extracellular matrix (ECM) proteins to promote adhesion of cells from the matrix, thereby inducing a biological state conducive to cell migration. SPARC is also thought to play an important role in tissue remodelling, angiogenesis, embryonic development and tumourigenesis. The current study set out to examine both the transcript levels of SPARC and the presence of the molecule in breast cancer tissue and to demonstrate if a link existed between the levels of SPARC and the clinical outcome. Breast tumour tissues (n=120) and non-neoplastic mammary tissues (n=32) were studied. Protein levels of SPARC were assessed using immunohistochemistry. Transcript levels of SPARC were analysed using RT-PCR. The levels were correlated with nodal status, grade, prognosis and long-term survival (10 years). Transcript levels of SPARC were found to be significantly higher in tumour tissue when compared to normal background breast tissue. This fact was mirrored when comparing levels of SPARC in ductal tumours with levels in lobular and other types of tumour. A high level of SPARC was also found in Grade 3 and TNM2 and TNM4 tumours. Node-positive tumours also exhibited higher levels of SPARC than node-negative tumours . It was also noted that SPARC was present in high levels in NPI 2 and NPI 3 tumours. Over a 6 year follow-up, high levels of SPARC was seen to be significantly associated with the overall survival of the patients (P=0.0198). However, there was no significant correlation with disease-free survival. It is concluded that SPARC plays a crucial role in tumour development in breast cancer and as such has a significant bearing on patient prognosis and long-term survival.
Similar articles
- Gamma-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells.
Watkins G, Martin TA, Bryce R, Mansel RE, Jiang WG. Watkins G, et al. Prostaglandins Leukot Essent Fatty Acids. 2005 Apr;72(4):273-8. doi: 10.1016/j.plefa.2004.12.004. Prostaglandins Leukot Essent Fatty Acids. 2005. PMID: 15763439 - The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W, Mokbel R, Salhab M, Jiang WG, Reed MJ, Mokbel K. Al Sarakbi W, et al. Anticancer Res. 2006 Nov-Dec;26(6C):4985-90. Anticancer Res. 2006. PMID: 17214375 - Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
Jiang WG, Douglas-Jones AG, Mansel RE. Jiang WG, et al. Prostaglandins Leukot Essent Fatty Acids. 2006 Feb;74(2):125-34. doi: 10.1016/j.plefa.2005.10.005. Epub 2005 Dec 20. Prostaglandins Leukot Essent Fatty Acids. 2006. PMID: 16364620 - Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.
Nagaraju GP, Dontula R, El-Rayes BF, Lakka SS. Nagaraju GP, et al. Carcinogenesis. 2014 May;35(5):967-73. doi: 10.1093/carcin/bgu072. Epub 2014 Mar 27. Carcinogenesis. 2014. PMID: 24675529 Review. - Prognostic Significance of SPARC Expression in Breast Cancer: A Meta-Analysis and Bioinformatics Analysis.
Shi S, Ma HY, Han XY, Sang YZ, Yang MY, Zhang ZG. Shi S, et al. Biomed Res Int. 2022 Feb 15;2022:8600419. doi: 10.1155/2022/8600419. eCollection 2022. Biomed Res Int. 2022. PMID: 35211625 Free PMC article. Review.
Cited by
- Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma.
Cheng CT, Chu YY, Yeh CN, Huang SC, Chen MH, Wang SY, Tsai CY, Chiang KC, Chen YY, Ma MC, Liu CT, Chen TW, Yeh TS. Cheng CT, et al. Onco Targets Ther. 2015 Jul 28;8:1899-907. doi: 10.2147/OTT.S78728. eCollection 2015. Onco Targets Ther. 2015. PMID: 26251613 Free PMC article. - SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer.
Komiya K, Nakamura T, Nakashima C, Takahashi K, Umeguchi H, Watanabe N, Sato A, Takeda Y, Kimura S, Sueoka-Aragane N. Komiya K, et al. Onco Targets Ther. 2016 Oct 27;9:6663-6668. doi: 10.2147/OTT.S114492. eCollection 2016. Onco Targets Ther. 2016. PMID: 27822069 Free PMC article. - SPARC: a matricellular regulator of tumorigenesis.
Arnold SA, Brekken RA. Arnold SA, et al. J Cell Commun Signal. 2009 Dec;3(3-4):255-73. doi: 10.1007/s12079-009-0072-4. Epub 2009 Oct 7. J Cell Commun Signal. 2009. PMID: 19809893 Free PMC article. - Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.
Spratlin JL, Mulder KE. Spratlin JL, et al. Int J Mol Sci. 2011;12(9):5895-907. doi: 10.3390/ijms12095895. Epub 2011 Sep 14. Int J Mol Sci. 2011. PMID: 22016635 Free PMC article. Review. - Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Von Hoff DD, et al. J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969517 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous